Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 5/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431169 | 0.85 | EGFR (0.48) | EPHA2EPHB4KDREGFRKDM4E | |
| SCHEMBL4423957 | 0.80 | KDR (0.60) | KDREGFRKDM4E | |
| SCHEMBL4421964 | 0.77 | MAP4K4 (0.56) | EPHA2EPHB4KDRPDGFRBTLR9 | |
| SCHEMBL4427451 | 0.74 | EGFR (0.52) | KDREGFR | |
| SCHEMBL4427550 | 0.73 | EGFR (0.67) | EPHA2EPHB4KDREGFRKDM4E | |
| SCHEMBL4430065 | 0.73 | EGFR (0.68) | KDREGFR | |
| SCHEMBL2915953 | 0.72 | PDGFRB (0.76) | PDGFRBPDGFRA | |
| SCHEMBL23216662 | 0.72 | SUV39H2 (0.50) | TLR9ALK | |
| SCHEMBL29886110 | 0.72 | SUV39H2 (0.50) | TLR9ALK | |
| SCHEMBL2909826 | 0.71 | CSF1R (0.75) | CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| EP-1272185-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1218353-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca UK Limited (GB) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |